Veradermics (NYSE:MANE) Sees Large Volume Increase – Here’s Why

Shares of Veradermics, Incorporated (NYSE:MANE) saw strong trading volume on Thursday. Approximately 437,247 shares traded hands during trading, a decline of 29% from the previous session’s volume of 616,318 shares. The stock last traded at $131.4130 and had previously closed at $110.95.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. UBS Group set a $170.00 price target on shares of Veradermics in a research note on Wednesday, July 15th. Jefferies Financial Group upped their target price on shares of Veradermics from $138.00 to $182.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Wall Street Zen upgraded shares of Veradermics from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Veradermics in a report on Friday, August 21st. Finally, Citigroup restated a “buy” rating on shares of Veradermics in a research note on Tuesday, September 15th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $153.00.

Veradermics Price Performance

The stock has a market capitalization of $5.29 billion and a P/E ratio of -66.87. The stock’s 50-day simple moving average is $107.24 and its 200 day simple moving average is $99.76.

Veradermics (NYSE:MANE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, meeting the consensus estimate of ($0.58). As a group, analysts expect that Veradermics, Incorporated will post -2.74 earnings per share for the current fiscal year.

Insider Activity at Veradermics

In other news, Director John W. Childs sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a total transaction of $10,712,000.00. Following the transaction, the director owned 194,117 shares in the company, valued at approximately $20,793,813.04. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Timothy August Durso sold 43,500 shares of Veradermics stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $107.82, for a total value of $4,690,170.00. Following the sale, the insider directly owned 78,142 shares of the company’s stock, valued at approximately $8,425,270.44. The trade was a 35.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 961,000 shares of company stock valued at $103,120,220 in the last 90 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Montanova Capital LLC bought a new position in Veradermics during the 2nd quarter worth $512,533,000. Bamco Inc. NY boosted its position in shares of Veradermics by 284.8% in the second quarter. Bamco Inc. NY now owns 229,581 shares of the company’s stock valued at $28,225,000 after acquiring an additional 169,913 shares during the period. Seven Fleet Capital Management LP bought a new stake in shares of Veradermics in the second quarter valued at about $9,835,000. Wellington Management Group LLP acquired a new position in shares of Veradermics in the second quarter valued at about $8,425,000. Finally, Private Capital Advisors Inc. increased its position in Veradermics by 158.4% during the third quarter. Private Capital Advisors Inc. now owns 6,291 shares of the company’s stock worth $763,000 after acquiring an additional 3,856 shares during the period.

Veradermics Company Profile

Veradermics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for dermatologic diseases. The company’s research and development efforts are aimed at addressing conditions that affect the skin, hair and nails, with an emphasis on treatments designed to improve patient outcomes and quality of life.

Veradermics is advancing a pipeline of investigational dermatology products across multiple disease areas. Its activities include the discovery, clinical development and potential commercialization of prescription therapies for conditions with unmet medical needs.